Name | Frunevetmab |
---|
Description | Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats[1][2]. |
---|---|
Related Catalog | |
Target |
Kd: 20 pM (NGF)[2] |
In Vitro | Frunevetmab (NV-02) neutralizes NGF with high affinity and potency and does not bind complement[2]. |
In Vivo | Frunevetmab (1.0-2.8 mg/kg; s.c; on days 0, 28, and 56) shows positive treatment effects in cats with naturally-occurring OA pain and associated mobility impairment and disability[1]. Animal Model: Cats with naturally-occurring OA pain and associated mobility impairment and disability[1] Dosage: 1.0-2.8 mg/kg Administration: s.c; 3 times at 28-day intervals; on days 0, 28, and 56 Result: Reliefed the pain from osteoarthritis in cats. |
References |
No Any Chemical & Physical Properties |